Academy Capital Management Sells 32 Shares of IDEXX Laboratories, Inc. $IDXX

Academy Capital Management cut its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the second quarter, HoldingsChannel.com reports. The firm owned 35,762 shares of the company’s stock after selling 32 shares during the period. IDEXX Laboratories accounts for approximately 2.7% of Academy Capital Management’s investment portfolio, making the stock its 13th biggest holding. Academy Capital Management’s holdings in IDEXX Laboratories were worth $19,181,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in IDXX. GAMMA Investing LLC raised its holdings in IDEXX Laboratories by 42.7% in the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company’s stock worth $918,000 after purchasing an additional 654 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock worth $49,000 after purchasing an additional 113 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in IDEXX Laboratories by 15.0% in the first quarter. Sequoia Financial Advisors LLC now owns 1,937 shares of the company’s stock worth $813,000 after purchasing an additional 252 shares in the last quarter. Diversified Trust Co bought a new position in IDEXX Laboratories in the first quarter worth about $633,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in IDEXX Laboratories by 26.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 33,477 shares of the company’s stock worth $13,928,000 after purchasing an additional 7,080 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $640.85 on Monday. The business’s 50 day moving average price is $638.40 and its 200 day moving average price is $560.29. The firm has a market cap of $51.27 billion, a P/E ratio of 53.36, a P/E/G ratio of 4.15 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the sale, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares in the company, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last quarter. Company insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a report on Friday, August 15th. Piper Sandler restated a “neutral” rating and set a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. UBS Group initiated coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price target on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Saturday. Finally, Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.